Why CheckMate-026 Failed to Show PFS Improvement With Nivolumab in Lung Cancer


Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses why CheckMate-026 was not successful in showing an improvement in progression-free survival (PFS) for patients with advanced non-small cell lung cancer.

Related Videos
Related Content